A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Colistimethate (Colistimethate)

Polymyxin-class Antibacterial class · 4 generic manufacturers · 4 ANDAs filed at FDA.

First FDA approval2007-11-01
Generic availableYes · 4 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$16.35/unit
5 NDCs benchmarked, lowest of all strengths.
Average NADAC
$16.35
Across all dosage forms in distribution.
Highest NADAC
$16.35
Range is tight.
Plans with PA
46 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema8 entries indexed · 4 visible
What is Colistimethate used for?

Colistimethate is a Polymyxin-class Antibacterial medication tracked in Medicare Part D.

Is there a generic for Colistimethate?

Yes. 4 ANDAs filed at FDA, 4 generic manufacturers currently shipping.

How much does my plan pay for Colistimethate?

Across 329 Part D plans, Colistimethate averages $16.35/unit (NADAC). Lowest available: $16.35/unit. Highest in distribution: $16.35/unit.

Is Colistimethate on the FDA shortage list?

No. Colistimethate is not currently on the FDA Drug Shortage Database.

4 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Polymyxin-class Antibacterial1 alternative in D1
01
Polymyxin B
Brand: POLYMYXIN B
Lowest NADAC
4Generic mfrs
$29,910CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (5 approvals on file) · NADAC unit costs: CMS NADAC weekly file (5 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.